The University of Southampton
University of Southampton Institutional Repository

Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EPPIA)

Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EPPIA)
Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EPPIA)
Summary: This report describes the epidemiology, burden, and treatment of osteoporosis in the 27 countries of the European Union (EU27).

Introduction: Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risk of fragility fractures which represent the main clinical consequence of the disease. Fragility fractures are associated with substantial pain and suffering, disability and even death for affected patients and substantial costs to society. The aim of this report was to characterize the burden of osteoporosis in the EU27 in 2010 and beyond.

Methods: The literature on fracture incidence and costs of fractures in the EU27 was reviewed and incorporated into a model estimating the clinical and economic burden of osteoporotic fractures in 2010.

Results: Twenty-two million women and 5.5 million men were estimated to have osteoporosis; and 3.5 million new fragility fractures were sustained, comprising 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures (i.e. fractures of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum and other femoral fractures). The economic burden of incident and prior fragility fractures was estimated at € 37 billion. Incident fractures represented 66 % of this cost, long-term fracture care 29 % and pharmacological prevention 5 %. Previous and incident fractures also accounted for 1,180,000 quality-adjusted life years lost during 2010. The costs are expected to increase by 25 % in 2025. The majority of individuals who have sustained an osteoporosis-related fracture or who are at high risk of fracture are untreated and the number of patients on treatment is declining.

Conclusions: In spite of the high social and economic cost of osteoporosis, a substantial treatment gap and projected increase of the economic burden driven by the aging populations, the use of pharmacological interventions to prevent fractures has decreased in recent years, suggesting that a change in healthcare policy is warranted.
1862-3522
136
Hernlund, E.
cd9762b6-9817-42fc-adba-8e90d33018eb
Svedbom, A.
3f3a5ff8-d010-4139-b1b6-47f5357f3810
Ivergard, M.
165a74bf-8e8d-4720-9ff9-45134425bd38
Compston, J.
b64c0d0e-97dd-44c8-97ba-f756f0bc966d
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Stenmark, J.
32e7f186-7e38-4f03-9e95-3797e51edc15
McCloskey, E.V.
38518227-db8f-4a53-88a6-462f469151de
Jonsson, B.
6971845f-f173-4620-a78f-e366a78688c4
Kanis, J.
d8c75fae-089a-46ed-8c71-8690dd1a967b
Hernlund, E.
cd9762b6-9817-42fc-adba-8e90d33018eb
Svedbom, A.
3f3a5ff8-d010-4139-b1b6-47f5357f3810
Ivergard, M.
165a74bf-8e8d-4720-9ff9-45134425bd38
Compston, J.
b64c0d0e-97dd-44c8-97ba-f756f0bc966d
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Stenmark, J.
32e7f186-7e38-4f03-9e95-3797e51edc15
McCloskey, E.V.
38518227-db8f-4a53-88a6-462f469151de
Jonsson, B.
6971845f-f173-4620-a78f-e366a78688c4
Kanis, J.
d8c75fae-089a-46ed-8c71-8690dd1a967b

Hernlund, E., Svedbom, A., Ivergard, M., Compston, J., Cooper, C., Stenmark, J., McCloskey, E.V., Jonsson, B. and Kanis, J. (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EPPIA). Archives of Osteoporosis, 8 (1-2), 136. (doi:10.1007/s11657-013-0136-1). (PMID:24113837)

Record type: Article

Abstract

Summary: This report describes the epidemiology, burden, and treatment of osteoporosis in the 27 countries of the European Union (EU27).

Introduction: Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risk of fragility fractures which represent the main clinical consequence of the disease. Fragility fractures are associated with substantial pain and suffering, disability and even death for affected patients and substantial costs to society. The aim of this report was to characterize the burden of osteoporosis in the EU27 in 2010 and beyond.

Methods: The literature on fracture incidence and costs of fractures in the EU27 was reviewed and incorporated into a model estimating the clinical and economic burden of osteoporotic fractures in 2010.

Results: Twenty-two million women and 5.5 million men were estimated to have osteoporosis; and 3.5 million new fragility fractures were sustained, comprising 610,000 hip fractures, 520,000 vertebral fractures, 560,000 forearm fractures and 1,800,000 other fractures (i.e. fractures of the pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum and other femoral fractures). The economic burden of incident and prior fragility fractures was estimated at € 37 billion. Incident fractures represented 66 % of this cost, long-term fracture care 29 % and pharmacological prevention 5 %. Previous and incident fractures also accounted for 1,180,000 quality-adjusted life years lost during 2010. The costs are expected to increase by 25 % in 2025. The majority of individuals who have sustained an osteoporosis-related fracture or who are at high risk of fracture are untreated and the number of patients on treatment is declining.

Conclusions: In spite of the high social and economic cost of osteoporosis, a substantial treatment gap and projected increase of the economic burden driven by the aging populations, the use of pharmacological interventions to prevent fractures has decreased in recent years, suggesting that a change in healthcare policy is warranted.

Full text not available from this repository.

More information

Published date: October 2013
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 359368
URI: http://eprints.soton.ac.uk/id/eprint/359368
ISSN: 1862-3522
PURE UUID: e64c4839-7b18-4072-b8a0-4cadb8945e42
ORCID for C. Cooper: ORCID iD orcid.org/0000-0003-3510-0709

Catalogue record

Date deposited: 30 Oct 2013 14:43
Last modified: 17 Dec 2019 01:56

Export record

Altmetrics

Contributors

Author: E. Hernlund
Author: A. Svedbom
Author: M. Ivergard
Author: J. Compston
Author: C. Cooper ORCID iD
Author: J. Stenmark
Author: E.V. McCloskey
Author: B. Jonsson
Author: J. Kanis

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×